Acerus Buys Back All Remaining U.S. Rights for NATESTO From Aytu
Executive Summary
Aytu BioScience Inc. licensed exclusive US marketing rights to Acerus Pharmaceuticals Corp.'s Natesto (testosterone), a nasal gel FDA-approved for testosterone replacement therapy in adult males diagnosed with hypogonadism.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
- Topical Delivery
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice